The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Daily Archives: March 4, 2017
Woolly mammoths experienced a genomic meltdown just before extinction – Science Daily
Posted: March 4, 2017 at 12:49 am
Science Daily | Woolly mammoths experienced a genomic meltdown just before extinction Science Daily Dwindling populations created a "mutational meltdown" in the genomes of the last wooly mammoths, which had survived on an isolated island until a few thousand years ago. Rebekah Rogers and Montgomery Slatkin of the University of California, Berkeley, ... Mammoth Genome Analysis Points to Pre-Extinction Genome Declines The last, lonely woolly mammoths faced a 'genomic meltdown' DNA clues to why woolly mammoth died out |
See the article here:
Woolly mammoths experienced a genomic meltdown just before extinction - Science Daily
Posted in Genome
Comments Off on Woolly mammoths experienced a genomic meltdown just before extinction – Science Daily
Genome editing: Pressing the ‘delete’ button on DNA – Phys.Org
Posted: at 12:49 am
March 2, 2017 Deletion of genomic DNA by paired CRISPR. Cas9 proteins (scissors) are guided to their target sites by single guide RNAs (sgRNAs, orange ribbons). The target region in between is removed. CRISPETa software enables researcher to design such deletion experiments quickly and conveniently. Credit: Pulido-Quetglas et al, CC BY
Until recently, genomics was a "read-only" science, but scientists have developed a tool for quick and easy deletion of DNA in living cells. This software, published in PLOS Computational Biology, will boost efforts to understand the vast regions of non-coding DNA, or "Dark Matter", in our DNA and may lead to discovery of new disease-causing genes and potential new drugs.
CRISPR-Cas9 is a revolutionary technique for editing genomes and until recently, most studies employing it were aimed at silencing protein-coding genes, the best-studied part of our genome. However our genome consists of 99% of DNA that does not encode any protein. Often described as the "Dark Matter" of the genome, this "non-coding DNA" is recognised to be crucially important for understanding all aspects of human biology, including disease and evolution.
The Johnson lab recently created a tool based on CRISPR-Cas9, called "DECKO", which can be used to delete any desired piece of non-coding DNA. The unique advantage of DECKO is that it uses two individual sgRNAs, acting like two "molecular scissors" that snip out a piece of DNA. The approach was widely adopted, but as no software was available for designing the pairs of sgRNAs that are required, designing deletion experiments was time-consuming.
In response to this, the researchers in this study led by Carlos Pulido, created a software pipeline called CRISPETa, a flexible solution for designing CRISPR deletion experiments. The user tells CRISPETa what region they wish to delete, and the software returns a set of optimised pairs of sgRNAs that can directly be used by experimental researchers. One of the key features is that it can create designs at high scales, with future screening experiments in mind.
The researchers showed that CRISPETa designs efficiently delete their desired targets in human cells. Most importantly, in those regions that give rise to RNA molecules, the researchers showed that the RNA molecules also carry the deletion.
"Ultimately, we expect that CRISPR deletion and other genome engineering tools to lead to a revolution in our ability to understand the genomic basis of disease, particularly in the 99% of DNA that does not encode proteins. Apart from being used as a basic research tool, CRISPR may even be used in the future as a powerful therapeutic to reverse disease-causing mutations," adds Rory Johnson.
CRISPETa is designed for use by non-experts so that it can be useful for scientific researchers, from even the most modest experimental laboratory. These users may, for example, delete a suspected functional region of non-coding DNA, and test the outcome on cellular or molecular activity. This software will also be potentially valuable for groups aiming to utilise CRISPR deletion for therapeutic purposes, by for example, deleting a region of non-coding DNA that is suspected to cause a disease state.
"We hope that this new software tool will allow the greatest possible number of researchers to harness the power of CRISPR deletion in their research," says Carlos Pulido, the student who wrote the CRISPETa software.
Explore further: Modifying fat content in soybean oil with the molecular scissors Cpf1
More information: Pulido-Quetglas C, Aparicio-Prat E, Arnan C, Polidori T, Hermoso T, Palumbo E, et al. (2017) Scalable Design of Paired CRISPR Guide RNAs for Genomic Deletion. PLoS Comput Biol 13(3): e1005341. DOI: 10.1371/journal.pcbi.1005341
A team from the Center for Genome Engineering, within the Institute for Basic Research (IBS), succeeded in editing two genes that contribute to the fat contents of soybean oil using the new CRISPR-Cpf1 technology: an alternative ...
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice. The unexpected findings, ...
Scientists at the Center for Genome Engineering, within the Institute for Basic Science (IBS), in collaboration with KIM Eunji (ToolGen Inc.) and KIM Jeong Hun (Seoul National University) have engineered the smallest CRISPR-Cas9 ...
Cystic fibrosis, sickle cell anemia, Huntington's disease and phenylketonuria are all examples of disorders caused by the mutation of a single nucleotide, a building block of DNA. The human DNA consists of approximately 3 ...
Scientists have developed a process that improves the efficiency of CRISPR, an up-and-coming technology used to edit DNA.
Genome editing using CRISPR/Cas9 "gene scissors" is a powerful tool for biological discovery and for identifying novel drug targets. In pooled CRISPR screens, a large number of cells are edited simultaneously using CRISPR ...
Within the human digestive tract, there are trillions of bacteria, and these communities contain hundreds or even thousands of species. The makeup of those populations can vary greatly from one person to another, depending ...
What makes a cluster of cells become a liver, or a muscle? How do our genes give rise to proteins, proteins to cells, and cells to tissues and organs?
The scientists who uncovered why zebras have black and white stripes (to repel biting flies), took the coloration question to giant pandas in a study published this week in the journal Behavioral Ecology.
Research by the University of Southampton has found that methods used to predict the effect of species extinction on ecosystems could be producing inaccurate results. This is because current thinking assumes that when a species ...
Zika may be spread by as many as 35 species of mosquitoes, including seven found in the United States, according to a predictive model created by University of Georgia ecologists and published Tuesday in the journal, eLife.
Out of the more than 300,000 plant species in existence, only three speciesrice, wheat, and maizeaccount for most of the plant matter that humans consume, partly because in the history of agriculture, mutations arose ...
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
See the original post:
Genome editing: Pressing the 'delete' button on DNA - Phys.Org
Posted in Genome
Comments Off on Genome editing: Pressing the ‘delete’ button on DNA – Phys.Org
Genome Mining of Natural Products Could Lead to Novel Therapeutics – Genetic Engineering & Biotechnology News
Posted: at 12:49 am
Scientists at the University of Illinois,led by associate professor of chemistry Douglas Mitchell, Ph.D., report the development of a tool that searches through microbial genomes, identifying clusters of genes that indicate an organism's ability to synthesize therapeutically promising molecules.
In aNature Chemical Biologyarticle ("A New Genome-Mining Tool Redefines the Lasso Peptide Biosynthetic Landscape"), lead authors Jonathan Tietz, Ph.D., and Christopher Schwalen and their colleagues in Mitchell's laboratory describe how their custom software learns to recognize predictive genomic features.
"With genome sequencing going at the pace it has...there's a dearth of functional information about what these genes are doing," Dr. Mitchell said. "It becomes increasingly important to make sense of and interpret metabolic pathways, especially biosynthetic gene clusters encoded by microbes."
His group is particularly interested in a class of molecules commonly referred to as RiPPs (ribosomally synthesized and post-translationally modified peptides). RIPPsmay seem unfamiliar, but they are already present in the average consumer's daily life. A bacterially produced RiPP called nisin, for example, has been used as a pathogen-fighting additive in dairy products, meats, and beverages such as beer since the 1960s.
"RiPPs have some particular advantages compared to other, more traditional, classes of natural products. They're usually larger and more structurally complex," which allows them to interact with cellular machinery in ways a smaller molecule cannot, Dr. Tietz explained. More points of contact with their cellular targets means RiPPs can hang on better and perform more complicated tasks. "At the same time, despite their complexity, RiPP biosynthesis...makes for greater potential for genetic re-engineering of natural products to tailor physical and pharmacological properties," he noted.
For all their advantages, RiPPs present a challenge; it is hard to discover new ones. Traditionally, researchers found potentially useful natural products by screening microbes based on their biological activity. After decades of such efforts, which revealed a range of products including some RiPPs, searches turn up the same common compounds over and over again.
Dr. Mitchell and colleagues are members of a multilaboratory research group at the Carl R. Woese Institute for Genomic Biology (IGB) that has found a way to uncover novel natural productsgenome mining.The Mining Microbial Genomes research theme at the IGB aims to speed drug discovery by searching through the genomes of microbes, essentially skimming through cells' recipe books to see what they might be able to produce, before actually persuading them to do so in a laboratory setting. In this way, researchers can greatly increase the odds that they will isolate a compound that has never been seen before. However, this method relies on the ability to predict what a group of genes might be capable of producing.
"In a practical sense the question became, is there a better way to harness available genomes for augmenting these discovery pipelines," said Schwalen. "That's where we started."
Dr. Mitchell's group faced a tough challenge: creating software that could recognize the groups of genes whose products work together to synthesize a RiPP. They decided to make it even tougher by focusing on a class of RiPPs called lasso peptides, named for their looping structure. The clusters of genes that produce lasso peptides are small and generic-looking, making them difficult to identify even in a manual search.
"If you want to show that you have a useful tool, you pick the hardest example," Dr. Mitchell said. "But also, as a chemist, lasso peptides are extremely interesting. Peptides that are used as drugs cannot be given orally" because they would be digested, he explained. "Lasso peptides are different. You can actually boil these, you can throw proteases at them, you can autoclave them and they don't lose their activity; they are basically a little peptide knot that is extremely resistant to such assaults."
The informatics tool that Mitchell's laboratory designed, named RODEO (Rapid Open reading frame Description and Evaluation Online), dealt with the lasso challenge in part through a machine learning approach. They trained the software on known examples of lasso-producing gene clusters, allowing the program to hone in on key features. The resulting software identified promising gene clusters in a broad array of microbial genomes, and could be customized to search for the gene clusters of other classes of RiPPs as well.
RODEO identified 1300 novel lasso peptides, including several with particularly unusual structures that make them promising as potential therapeutics; the researchers confirmed that the empirically determined structures matched those predicted by the software.
"We can now use genomic prioritization to find molecules that without any doubt are structurally novel," said Dr. Mitchell. "The challenge is, is that a useful molecule or not? But the more molecules you can connect to genes, the better informed we're going to get. So that's the next 10 years of discovery."
Read the rest here:
Genome Mining of Natural Products Could Lead to Novel Therapeutics - Genetic Engineering & Biotechnology News
Posted in Genome
Comments Off on Genome Mining of Natural Products Could Lead to Novel Therapeutics – Genetic Engineering & Biotechnology News
Human Genome Project 2: Should scientists synthesize our entire genetic blueprint? – Genetic Literacy Project
Posted: at 12:49 am
In May 2016, scientists, lawyers and government representatives converged at Harvard to discuss the Human Genome Project-Write (HGP-Write), a plan to build whole genomes out of chemically synthesised DNA. It will build on the $3 billion (2.3bn) Human Genome Project, which mapped each letter in the human genome.
Moving beyond reading DNA to writing DNA is a natural next step, concedes Francis Collins, director of the US National Institutes of Health. He warns, however, that any project with real-world implications would require extensive discussion from different perspectives, most especially including the general public.
[N]one of the projects deliverables will be as exciting or as evocative as a baby, [Andrew Hessel, a researcher with the Bio/Nano research group at software company Autodesk] says. Some of the things that were said [after the meeting] were so ludicrous that it allowed us to get through that bubble of misinformation and misinterpretation quickly.
I want it to be as open and transparent as possible, says Hessel, and to keep up as much interest in this powerful universal technology, which will enable us to bring our intention into the machinery we call life. And boy, do we need to get good at it.
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post:Humans 2.0: these geneticists want to create an artificial genome by synthesising our DNA
Excerpt from:
Human Genome Project 2: Should scientists synthesize our entire genetic blueprint? - Genetic Literacy Project
Posted in Genome
Comments Off on Human Genome Project 2: Should scientists synthesize our entire genetic blueprint? – Genetic Literacy Project
Genomics literacy critical to San Diego and nation – The San Diego Union-Tribune
Posted: at 12:49 am
The word genome is nearing its 100th birthday. A combination of the German word for gene (gene) and the Greek suffix for body (ome), it was first used in a 1920 botany textbook to describe the entire chromosome set of a given species.
Its surprising that the word is so old because its not a word many of us heard in school. In most schools, teachings about genetics are fairly limited and provide only a basic introduction to the chemical structure of DNA and Mendelian inheritance patterns. Its unfortunate that there arent more educational resources directed toward genetics and genomics, especially in San Diego, because this is a field that is critically important to continuing our regions legacy of scientific innovation, contributing to responsible science policymaking and to the continued growth of our local economy.
Today, genomics is being used to answer a wide range of scientific questions and provide improvements to human health and the human experience in many ways. Data from genome sequencing or genotyping can help identify those at highest risk for cancer and the best treatments for those who are diagnosed with the disease. It can identify the underlying causes of many rare genetic diseases. DNA is used for solving crimes, detecting the sources of foodborne illness, controlling outbreaks of infectious diseases, and the list goes on and on.
To continue this innovation, we need people with a range of skill sets who understand genetics, can work with genomic data, and can translate it into patient care.
As we think about some of the biggest science policy questions of our time, genetics plays a critical role. Responsible policy-making will require policymakers and society to understand genomics to answer big questions whose decisions have great potential to impact society. There are so many policy questions that hinge on genomics.
Should genetic tools like CRISPR be used to modify species of pests like mosquitoes and ticks in order to prevent the spread of diseases like malaria, Zika and Lyme?
Is it ethical to use mitochondrial DNA from a donor egg, nuclear DNA from a mothers egg and a sperm to prevent mitochondrial disease in a baby?
Should we modify food crops and animal species to enable them to thrive in areas of the world whose climates are changing?
Our collective decision-making should rely in good science.
And then theres the matter of our regional heritage of innovation and ensuring the ongoing success of the genomics powerhouses that helped San Diego earn its reputation as the genomics capital of the world.
According to CONNECTs most recent San Diego Innovation Report, in 2015, there were 82 new life sciences companies created in San Diego, undoubtedly many of them genomics companies. With the pioneers of genomic research and medicine like J. Craig Venter, Eric Topol, Stephen Kingsmore, Rob Knight and others choosing to make San Diego home, we have all the makings of success. But where will companies like Illumina, Human Longevity Inc., Epic Sciences, Trovagene and others be without a robust pipeline of workers who understand genomics?
Since STEM disciplines, understanding and talent are so fundamental to our success, Illumina has been quietly funding programs aimed at increasing genomic literacy in San Diego for years. Weve leveraged the generosity of our employees to lend their time and talent to hosting student visits to our UTC headquarters, hosting hundreds of students over the past few years to spark an interest in the power of the genome to change our lives. Our desire to ensure these programs grow and continue led us to establish the Illumina Foundation last year and were proud that it is this year the presenting sponsor of the Biocom Institute Festival of Science and Engineering, San Diego, which kicks off with EXPO Day at Petco Park on Saturday and continues with events throughout the county through March 12.
We hope that our ongoing commitment to growing genomic literacy in the communities where we live and work will not only help create 21st-century jobs in San Diego, but also continue to drive scientific breakthroughs and innovation here and around the globe. Together, by engaging in genomics, its social impacts and the opportunities it creates we have the potential to dramatically improve human health and the human condition as we step forward into the future.
DeSouza is president and CEO of Illumina.
More here:
Genomics literacy critical to San Diego and nation - The San Diego Union-Tribune
Posted in Human Longevity
Comments Off on Genomics literacy critical to San Diego and nation – The San Diego Union-Tribune
8 Principles for Leaders to Make the Most of the Exponential Age – Singularity Hub
Posted: at 12:49 am
How do top CEOs lead during this exponential age?
How do you manage the explosion of information and onslaught of increasing competition?
How do you sort through the abundance of opportunity and prevent getting burned out?
How do you maintain agility during todays tsunami of change?
Todays blog is the first of three parts deriving insights and advice from three incredible, forward-thinking leaders: Beth Comstock, Sue Siegel, and Arianna Huffington (their bios are below).
Beth, Sue and Arianna participated in my 2017 Abundance 360 CEO Summit in a module called Exponential Leadership.
There is post in this blog for any exponential leader, so lets dive in.
Beth Comstock is the vice chairman of GE. In this capacity, she leads GE's efforts to accelerate new growth. She heads GE's business innovations including GE Lighting, GE Ventures, GE Licensing, GE sales, marketing and communications. And since 2008, she has served as GE's Chief Marketing Commercial Officer.
Sue Siegel is the CEO of GE Ventures. She heads their growth innovation business investing, licensing new creations. Previously, Sue was the President of Affymetrix, and shes had 30 years of combined commercial experience. She's also on my board at Human Longevity Inc., which I'm very proud of, and GE is an investor in HLI.
Arianna Huffington is the founder of Huffington Post, the Founder and CEO of Thrive Global and a fellow Greek. She is the author of 15 books, including "Thrive - The Sleep Revolution. She's been named by Time Magazine and by all of us as one of the most influential people on the planet.
All three of these leaders had extraordinary insights to share about leadership in exponential times.
For part 1, lets dive into Beths top takeaways.
Beth has an extraordinary mindset as a leader at GE.
These days, I think you have to be constantly thinking about what's next, what's new, and how do I adapt, Beth began, during her address to A360 members.
Beth outlined eight principles for exponential leadership. Read carefully.
1. Be a Mission-Based, Emergence Leader: If you're a leader today, your job is change and culture. It's a lot of other things, but it doesnt matter where you are in the organization, [the most important aspects] are change and culture. The old is going away (but it has not fully disappeared), the new is emerging and we're all trying to make sense of it. Change suddenly shows up and it's disruptive. An emergence leader is constantly focused on and ready for change.
2. Organize Around Information Flows: In the digital age, information moves fast. To keep up with information flows, you have to ditch hierarchy. There's no room for bureaucracy. It's about openness, candor, radical feedback and full transparency. If you organize your organization around these tenets, youll thrive. At GE, we've really reorganized ourselves as a digital industrial company digitizing everything we can get our hands on.
3. Empower Individuals: Build a team of people who are prepared for change and empower them to do great work. The question is: how do you get people to get excited to grab power and go for it? More autonomy.
4. Define your company's MO - Mindset Orientation: Mindset is everything. As a leader, you must provide the vision and then allow your teams to figure their way out. Create a mindset that incentivizes them to do what they need to do the fastest, best way they can. It means they may fail. You should encourage them to fail fast, learn from their mistakes, and keep going. At GE, this process is called FastWorks, and it's built on lean startup methodology.
5. Establish Feedback Loops: Exponential leaders must both give and receive feedbackand importantly, they have to actually use it. Beth offers three ideas here:
First: One of the things we've done at GE is we've actually gotten rid of our employee performance reviews. Anyone in the organization can give anyone feedback. I just did a Facebook Live event last week and one of my young colleagues in the company gave me some feedback. It wasn't so good... You weren't looking at the camera at the right point. You looked like you were distracted. It was hard feedback to receive, but it was encouraged.
Second: Beth suggests asking your team a very direct question that yields a lot of value: What is the one thing that is true that you think I dont want to hear? Beth comments that youll be amazed what youll learn. Its extremely valuable.
Third: Rather than doing long, convoluted employee surveys, stick to a simple feedback mechanism: Continue, or consider. You get feedback that says either Continue doing X or Consider changing X to make it better. Its really simple, fast and actionable.
6. Get Used to Living in the In-Between: Exponential leaders are comfortable with ambiguity and uncertainty. This is going to be key to survive the change that is coming. Beth advises, Get used to the ambiguity of working with people who know how to figure it out and who don't need as much instruction.
7. Mash Up Minds and Machines: Exponential leaders use technology to their advantage, combining the power of computing and data with human leadership. They must develop collaborations between people and machines, between artificial intelligence, machine learning, and the people operating in their company, their customers and their executives. Teams that dont do this will be left behind.
8. Prioritize Innovation and Observe Patterns That Block It: Innovating is really hard. Good leaders understand they have to navigate the tension. Sometimes leaders give up, and they don't hold their team accountable for growing. They themselves back off on it. And so is it any wonder that the people on the team deprioritize innovating? Its also important to stick around a while. I've been around my company a while, and it's only after a few years that you start to see the patterns and to understand what went wrong.
Change is coming. Exponential leaders must prepare for it and embrace it.
Beth concluded, I think we still need great leaders with vision, the ability to find and coach people, to encourage people, to help them renew themselves, to go forward
I'm a firm believer that the future still depends on great leaders who can constantly reinvent themselves. Beth Comstock, Vice-Chair, GE
Image Credit: Shutterstock
Go here to read the rest:
8 Principles for Leaders to Make the Most of the Exponential Age - Singularity Hub
Posted in Human Longevity
Comments Off on 8 Principles for Leaders to Make the Most of the Exponential Age – Singularity Hub
New Eczema Drug Promising in Early Trial – WebMD
Posted: at 12:49 am
Nemolizumab significantly reduced the itch and improved appearance of skin
WebMD News from HealthDay
By Steven Reinberg
HealthDay Reporter
THURSDAY, March 2, 2017 (HealthDay News) -- An experimental drug may significantly reduce the itching and improve the appearance of moderate to severe eczema, a new, preliminary trial finds.
Nemolizumab is a man-made, injectable antibody that acts against the protein that has been identified as playing a part in eczema, the international team of researchers said.
"The treatments for atopic dermatitis [eczema] have been disappointing because of their lack of efficacy and the long-term side effects," said Dr. Doris Day, a dermatologist at Lenox Hill Hospital in New York City. She had no role in the study.
"There are also issues with compliance, since the products often need to be applied to broad areas multiple times a day," she added.
Since this is a chronic condition, continued treatment is usually needed to maintain results, Day explained.
"The goal is to find a non-steroid treatment that is easy to follow, and with reliable results and minimal adverse effects," she said.
While the hope is always for a cure, the results of this trial "are encouraging and give hope to those suffering from moderate to severe atopic dermatitis [eczema] for an effective treatment to control their condition with good long-term outcomes," Day said.
The study was published March 2 in the New England Journal of Medicine and was funded by Tokyo-based Chugai Pharmaceutical Co. Ltd., the maker of nemolizumab.
Most types of eczema cause dry, itchy skin and rashes on the face, inside the elbows, behind the knees, and on the hands and feet. Scratching can cause the rash to turn red, swell and itch even more, according to the U.S. National Institutes of Health.
Eczema is not contagious. Its cause is not known, but is likely due to both genetic and environmental factors. It may get better or worse over time, but it is often a long-lasting disease.
In this 12-week trial, a team lead by Dr. Thomas Ruzicka, from the department of dermatology and allergology at Ludwig Maximilian University in Munich, Germany, randomly assigned 264 patients with moderate to severe eczema to one of three injectable doses of nemolizumab or placebo.
Read the rest here:
New Eczema Drug Promising in Early Trial - WebMD
Posted in Eczema
Comments Off on New Eczema Drug Promising in Early Trial – WebMD
J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab – Endpoints News
Posted: at 12:48 am
J&J has reaped the final harvest of Phase III data it is taking to regulators in search of a blockbuster approval for their psoriasis contender guselkumab.
J&J is widely expected to use this latest batch of reliably positive data to clean up on major approvals at the FDA and EMA. But its favorable late-stage comparisons with Humira may not count for so much these days, as the pharma giant is bringing up the rear of a parade of new drugs that got to the market first.
Novartis Cosentyx got out ahead 18 months ago and the Swiss pharma giant has followed with 4-year data tracking a solid success 43.5% in keeping skin cleared over the long haul. Eli Lilly backed its new drug Taltz in a major campaign last fall. And then Valeant ambled across the finish line with brodalumab now dubbed Siliq two weeks ago. Their drug, picked up at a discount from a disappointed AstraZeneca, also comes with a black box warning on suicidal thinking that will almost certainly squeeze its slice of the market down to a sliver.
Now comes J&J, a global powerhouse, with a contender it believes is already positioned for success.
As we saw in the first Phase III, VOYAGE 1, guselkumab handily outscored a placebo on two measures of complete or near-complete skin clearance in VOYAGE 2. And once again their IL-23 drug slapped aside Humira, with guselkumab versus adalimumab achieving an IGA 0/1 score of 84% versus 67.7% and a PASI 90 of 70% compared to 46.8%, respectively.
The results were remarkably similar, which is what you want to see, Philippe Szapary, VP for dermatology and gastroenterology in J&Js Immunology Clinical Development unit, tells me about his Phase III studies.Its very reassuring to see such amazing consistency.
J&Js third Phase III study looking at patients transferred to guselkumab after an inadequate response to their other psoriasis drug Stelara also looked good. The statement notes:
Patients who switched to guselkumab consistently showed greater improvement in their psoriasis between weeks 28 and 40, compared with patients who continued to receive Stelara, having twice as many office visits with at least a 2 point improvement in IGA from week 16, the studys primary endpoint, and an IGA score of 0 or 1.
J&J gained a new approval for Stelara last fall, adding Crohns to the label as the company looked to keep its performance in blockbuster territory. The new Navigate study also positions J&J to keep about 30% of psoriasis patients who dont respond well to Stelara in the fold, so to speak.
Investigators also reaped a satisfying profile on safety, with a somewhat better set of data on adverse effects compared to Humira, which remains a big player in this field as AbbVie continues to fight off biosimilar competition. There is also one more psoriasis drug waiting in the wings. Sun Pharma gained control of Mercks MK-3222, but it isnt expected to hit the market anytime soon.
The next step is to keep gathering data with extension studies that will take the 1800 patients enrolled for VOYAGE 1 and 2 out about five years. With a target lying upstream of IL-17 and TNF, he adds, investigators are hopeful that guselkumab will continue to perform well against competition long after it arrives on the market.
Go here to see the original:
J&J may be late to the psoriasis drug market party, but it's planning to make a splash with guselkumab - Endpoints News
Posted in Psoriasis
Comments Off on J&J may be late to the psoriasis drug market party, but it’s planning to make a splash with guselkumab – Endpoints News
Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? – FiercePharma
Posted: at 12:48 am
Yes, Valeant has a safety warning weighing down new psoriasis med Siliq as it prepares to enter the market. But its got another issue, too: the fact that its going up against some major spenders in the field.
When it launches, Siliq will take on fellow IL-17 meds Cosentyx from Novartis and Taltz from Eli Lilly, but it will also have to contend with the anti-TNF giantsAbbVies Humira included. As Wells Fargo analyst David Maris pointed out last month in a note to clients, the Illinois pharma spent $357 million on Humira advertising in 2015 alone.
It also regularly tops pharmas TV ad spending list, shelling out $35 million in January, according to tracker iSpot.tv.
That could be a problem for a company in financial straits as dire as Valeants; the debt-laden company has been plagued by default concerns since last year, thanks to years of debt-fueled M&A dealmaking under former skipper J. Michael Pearson.
And while the company plans to keep itsSG&A spending in 2017 between $2.6 billion and $2.7 billion, its got some other key priorities this year, too: Its planning to relaunch flopped female libido drug Addyi, and its expanding its primary care sales force for lead med Xifaxan in the wake of canceled GI unit deal talks with Japans Takeda.
The financial concerns add to the safety burden Valeant is already facing with its psoriasis newcomer. The med comes along with a black-box warning on suicide risks and a substantial risk-managing program, under which physicians and pharmacies will have to be certified toprescribe and dispensethe med and patients will have to signinformed consent agreements before taking it.
All things considered, we believeSiliqis a sub-competitive drug in a competitive market that Valeant cannot afford to compete in, Maris wrote following the products February FDA approval.
Valeants management, though, thinks Siliq can stand out from the crowd based on its clinical benefits. As CEO Joseph Papa told investors on the companys Q4 conference call, Siliqunlike its IL-17 peersis a receptor-blocker, and when you can actually block the receptor, you tend to get a better, a quicker response and also a response that is more durable.
And some analysts agree. Siliqoffers differentiation on efficacy parameters relative to competitors, Barclays Doug Tsao wrote to clients, noting that though Valeant is splitting profits down the middle with developer AstraZeneca, the 90% profit margins and relatively concentrated prescriber base makeSiliqan attractive opportunity even if Valeant can get 5% to 10% market share.
Read the original:
Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? - FiercePharma
Posted in Psoriasis
Comments Off on Does Valeant have the ad dollars to keep Siliq competitive in psoriasis? – FiercePharma
National Psoriasis Foundation 2016 Medical Professional Awards Winners – PR Newswire (press release)
Posted: at 12:48 am
Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.
Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.
Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women's Dermatologic Society.
Health Professional Volunteer of the Year Craig F. Teller, MDCraig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.
Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BCMs. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.
Aldredge is the past President of the national Dermatology Nurses' Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses' Association.
Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world's leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/national-psoriasis-foundation-2016-medical-professional-awards-winners-300416249.html
SOURCE National Psoriasis Foundation
Original post:
National Psoriasis Foundation 2016 Medical Professional Awards Winners - PR Newswire (press release)
Posted in Psoriasis
Comments Off on National Psoriasis Foundation 2016 Medical Professional Awards Winners – PR Newswire (press release)